Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1477-1485

  Pili, Roberto ^a   Kruszewski, Mark P ^a   Hager, Brant W ^a   Lantz, Julie ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ARYLBUTYRIC ACID DERIVATIVE; ISOTRETINOIN; MATRIGEL; PHENYLBUTYRATE; RETINOIC ACID RECEPTOR BETA; RETINOID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; GROWTH INHIBITORS; HUMANS; ISOTRETINOIN; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; TUMOR CELLS, CULTURED;

EID: 0035866341     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Retinoids, neoplasia and differentiation therapy
2. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid
3. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
4. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers
5. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells
6. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
7. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
8. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
9. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
10. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
11. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effect
12. Role of the histone deacetylase complex in acute promyelocytic leukaemia
13. Sodium butyrate inhibits histone deacetylation in cultured cells
14. Induction of reporter gene expression by inhibitors of histone deacetylase
15. Up-regulation and functional role of p21Wafl/Cip 1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate
16. Phase I study of phenylacetate administered twice daily to patients with cancer
17. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB
18. A decade of molecular biology of retinoic acid receptors
19. Two distinct actions of retinoid-receptor ligands
20. The RXR heterodimers and orphan receptors
21. Retinoic acid receptor-β as a prognostic indicator in stage I non-small-cell lung cancer
22. Methylation and silencing of the retinoic acid receptor-β gene in breast cancer
23. Differential expression of nuclear retinoid receptors in normal and malignant prostates
24. Transcriptional activation of the human p21(WAF1/C1P1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation
25. Retinoids in cancer therapy
26. 13-cis-Retinoic acid in the treatment of oral leukoplakia
27. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
28. Molecular epidemiology and retinoid chemoprevention of head and neck cancer
29. Anti-angiogenesis: New concept for therapy of solid tumors
30. Tumor angiogenesis: Therapeutic implications
31. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
32. Retinoids downregulate vascular endothelial growth factor/vascular permeability factor production by normal human keratinocytes
33. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma
34. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination
35. Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation
36. Stimulation of tissue-type plasminogen activator. Synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo
37. Nuclear receptors: Structure, function and involvement in disease
38. Medical significance of peroxisome proliferator-activated receptors
39. Peroxisome proliferator-activated receptors: Structures and function
40. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
41. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: Binding and activation by an aromatic fatty acid with clinical antitumor activity
42. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
43. Terminal differentiation of human breast cancer through PPARγ
44. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
45. Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints
46. Identification of a retinoic acid responsive element in the retinoic rednoic acid receptor β gene
47. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO
48. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells
49. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice
50. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice
51. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
52. Transcriptional upregulation of retinoic acid receptor β (RARβ) expression by phenylacetate in human neuroblastoma cells
53. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells
54. Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo
55. 15-Deoxy-Α12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
56. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
57. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
58. Activated macrophages induce vascular proliferation
59. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
60. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
61. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
62. Endothelial cell apoptosis induced by the peroxisome proliferator activated receptor (PPAR) ligand 15-deoxy-Α12,14-prostaglandin J2
63. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo